30DEC

Libyan International Conference for Health Sciences

The First Libyan International Conference for Health Sciences (2024): Open University, Tripoli, Libya
Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
https://app.periodikos.com.br/journal/medjpps/article/doi/10.5281/zenodo.14645927

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

review

A comprehensive analysis of disclosed synthetic strategies in prior arts from 2013-2024 (Part II) regarding the preparation of the renowned drug, Febuxostat, and its related scaffolds

Sanjay Sukumar Saralaya

http://dx.doi.org/10.5281/zenodo.14645927 Mediterr J Pharm Pharm Sci, Ahead of Print, 2025
PDF
PDF
Downloads: 0
Views: 29

Abstract

Abstract: This review segment (Part II) provides an essential collection of research disclosures about the synthesis of Febuxostat (Fb) and its closely associated scaffolds from 2013-2024. During the process, 87 research communications (as patents and journal articles) were collected from various global online research repositories, and the essential components were systematically tabulated in the article for better readability. This review article would provide a useful platform for the researchers to understand the past ventures on the synthesis of Fb and the knowledge of same can transform to develop some inventive or innovative ventures on the synthesis of Fb and its related scaffolds in the near future.

Keywords

Benzothioamide, Febuxostat prior arts raw materials, phenylthiazole, synthesis, reaction schemes

References

  1. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febuxostat for treating chronic gout. Cochrane Database of Systematic Reviews. 11 (11): CD008653. doi: 10.1002/14651858.CD008653.pub2
  2. Waller A, Jordan KM (2017) Use of Febuxostat in the management of gout in the United Kingdom. Therapeutic Advances in Musculoskeletal Disease. 9 (2): 55-64. doi: 10.1177/1759720x16682010
  3. Collison J (2018) Stepping up febuxostat to treat gout flares. Nature Reviews. Rheumatology. 14 (1): 4. doi: 10.1038/nrrheum.2017.193
  4. Sun R, Lu J, Li H, Cheng X, Xin Y, Li C (2020) Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial. Joint, Bone, Spine: Revue Du Rhumatisme. 87 (5): 461-466. doi: 10.1016/j.jbspin.2020.03.017
  5. Choi HK, Zhang Y, Dalbeth N (2022) When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy. Nature Reviews. Rheumatology. 18 (9): 543-549. doi: 10.1038/s41584-022-00804-5
  6. Shang Q, Du B, Mu L, Zhang L, Wang X, Lin T (2023) Clinical observation of Febuxostat in the treatment of gout patients with different body fat levels. Minerva Medica. 114 (3): 416-418. doi: 10.23736/S0026-4806.23. 08499-9
  7. Hainer BL, Matheson E, Wilkes RT (2014) Diagnosis, treatment, and prevention of gout. American Family Physician. 90 (12): 831-836.
  8. Dakkak M, Lanney H (2021) Management of gout: Update from the American college of rheumatology. American Family Physician. 104 (2): 209-210.
  9. James R, Paul BJ (2023) New and emerging therapies in gout. Rheumatology & Autoimmunity: 3 (2): 70-77. doi: 10.1002/rai2.12064
  10. Sokhi SS, Nath A, Tandon N, Prasad M (2013) Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid. EP2542540A1. European Patent Office.
  11. Shen R, Li Y, Tang J, He H, Yao C, Zhao F, Liu Y, Liu Q, Ma W (2013) Stable Febuxostat crystal. CN103396378A. China.
  12. Ge C (2013) New preparation method of Febuxostat. CN102936230A. China.
  13. Jetti RR, Bhogala BR, Beeravelli S (2013) Process for the preparation of Febuxostat polymorphs. WO2013076738A2. WIPO (PCT).
  14. Mizhiritskii M, Marom E, Rubnov S (2013) Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids. WO2013050996A2. WIPO (PCT).
  15. Shen R, Li Y, Tang J, He H, Liu Y, Yao C, Ma W (2013) Drug chemical compound for gout. CN103467412A. China.
  16. Zhang X, Bao J, Jiang Y, Xiao T, Xu F (2013) Preparation method of Febuxostat intermediate. CN103073465A. China.
  17. Kompella AK, Gampa VK, Kusumba S, Adibhatla KSBR, Nannapaneni VC (2013) Stable crystal form of Febuxostat and process for the preparation thereof. WO2013088449A1.WIPO (PCT).
  18. Zhou G, Liu X (2013) Synthetic method of Febuxostat. CN102964313A. China.
  19. Vellanki SR.P, Sahu A, Raavi S, Nuchu R, Dandala R (2013) Process for the preparation of 2-arylthiazole derivatives. US2013303780A1. United States.
  20. Zhou R (2013) Preparation method of Febuxostat. CN103058950A. China.
  21. Lv H, Zou J, Yang Y (2013) Preparation method of high-purity Febuxostat. CN103012311A. China.
  22. Kompella A, Gampa VGK, Adibhatla KSBR, Nannapaneni VC (2013) Process to prepare ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate. US20130172571A1. United States.
  23. Zhang G (2013) Preparation method and detection method of Febuxostat raw material. CN10303060A. China.
  24. Dwivedi SD, Prasad A, Roy RU, Patel MR (2013) Substantially pure salts of Febuxostat and processes for preparation thereof. US2013190366A1. United States.
  25. Luo Y, Zhang T, Su H (2013) Febuxostat pharmaceutical co-crystal and preparation method thereof. CN103044353A. China.
  26. Luo Y, Qu X, Yang Y, Lian L, Cao X, Hou Y,  Zhou G (2013) Novel Febuxostat pharmaceutical co-crystal and preparation method thereof. CN103058951A. China.
  27. Salaet-Ferre J, Marquillas-Olondriz F (2013) Process for preparing the crystalline form II of Febuxostat. EP2593442A1. European Patent Office.
  28. Marom E, Rubnov S (2013) Polymorphs of Febuxostat. US2013225830A1. United States.
  29. Wang L, Xia Q, Chen J (2013) Method for synthesizing p-hydroxyl thiobenzamide. CN103396347A. China.
  30. Wang S, Shi X, Lin Y (2013) 2-(3-cyano-4-alkoxy) phenyl-4-substituted thiazole-5-formic acid compound, composition as well as preparation methods and applications thereof. CN103333134A. China.
  31. Komiyama M (2013) Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound. CN103068807A. China.
  32. Zhang L, Ren Y, Li J (2013) Preparation method for Febuxostat. CN103304512A. China.
  33. Sun G, Zhou Y, Liu S, Chen J, Feng L, Ge M (2014) Preparation method of 2-(3-cyan-4-isobutoxyphenyl)-4-methylthiazole-5-formic acid A crystal. CN103739568A. China.
  34. Zhang Y (2014) 2-[3-cyano-4-isobutoxy phenyl]-4-methylthiazole-5-formic acid crystal forms and preparation method thereof. CN103936689A. China.
  35. Li N (2014) Preparation method of 3,4-substitituted thiobenzamide and application of 3,4-substitituted thiobenzamide in Febuxostat synthesis. CN104163782A. China.
  36. Li Q, Liu R, Liu J, Li R, Cheng P, Wang X, Li F (2014) Synthetic method of Febuxostat. CN103910695A. China. 
  37. Pranab C, Asok N, Sarbjot SS, Mohan P (2014) Process for the preparation of Febuxostat. US8916713B2. United States.
  38. Vallu VR, Desai KG, Patil SD, Agarwal R, Padi PR, Ghanta, MR (2014) Synthesis and characterization of process-related impurities of an anti-hyperuricemia drug-Febuxostat. Der Pharma Chemica. 6 (3): 300-311. Corpus ID: 98946187.
  39. Zhang L, Huang Z, Li J (2014) Febuxostat polymorph and preparation method thereof. CN103788009A. China.
  40. Parthasaradhi RB, Rathnakar RK, Muralidhara RD, Ramakrishna RM, Vamsi KB (2014) Process for Febuxostat. US20140112992A1. United states.
  41. Huang Q, Huang H (2014) Preparation methods of compound 2-(3-formyl-4-isobutoxy phenyl)-4-methyl thiazole-5-ethyl formate and Febuxostat. CN103880775A. China.
  42. Xie T, Xu Z, Zhou Y (2014) Febuxostat crystal form A and preparation method thereof. CN103588724A. China.
  43. Chen G, Su Q (2015) Method for preparing 4-substituted thiobenzamide derivative. CN104610110A. China.
  44. Lou H, Wang J, Chen T, Rao X (2015) Method for synthesizing high-purity ethyl 2-(3-aldehyde-4-isobutyloxyphenyl)-4-methylthiazole-5-formate. CN104529935A. China.
  45. Praveen C, Sreenadha CK, Vijay KA, Chandra SV (2015) Preparation of Febuxostat. US8969582B2. United States.
  46. Tamura T, Moriyama K, Tog H (2015) Facile one‐pot transformation of Arenes into aromatic nitriles under metal‐cyanide‐free conditions. European Journal of Organic Chemistry. 9: 2023-2029. doi: 10.1002/ejoc. 201403672
  47. Li Z, Li S (2015) Preparation method of 2-(3-cyano-4-hydroxyl) phenyl-4-methyl-5-thiazole ethyl formate. CN104478824A. China.
  48. Cui Y, Feng X (2015) Preparation method of Febuxostat intermediate. CN104418823A. China.
  49. Wang Q, Jin C, Zhang W Wang P (2016a) Method for preparing Febuxostat through one-pot process. CN106187940A. China.
  50. Wang Q, Guo Y, Wang M, Zhu W, Xu S (2016) Synthesis of 3-bromo-4-isobutyloxyphenyl carbothio-amide. Proceedings of the 2015 2nd International Conference on Machinery, Materials Engineering, Chemical Engineering and Biotechnology. 794-797. doi: 10.2991/mmeceb-15.2016.157
  51. Koftis TV, Neokosmidis E, Trakossas S, Panagiotidis T, Andreou T, Varvogli AA (2016) A novel process for the preparation of Febuxostat. CN105452228A. China.
  52. Kang Y, Gu J, Hu X (2016) Syntheses, structure characterization and dissolution of two novel cocrystals of Febuxostat. Journal of Molecular Structure. 1130: 480-486. doi: 10.1016/j.molstruc.2016.10.044
  53. Reddy MVB, Srinivasulu D, Sudhana SM, Srikanth B, Raju CN (2016) Inhibition of LPS-induced no production in RAW264.7 cell lines: synthesis and molecular modeling of α-ketophosphonates of Febuxostat. Phosphorus, Sulfur, and Silicon and the Related Elements. 191 (1): 144-149. doi: 10.1080/10426507.2015.1050018
  54. Wei C (2017) Method for controlling Febuxostat intermediate impurity. CN106366048A. China.
  55. Zhao X, Xia C, Zhang M (2017) Synthesis method of ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate. CN106518802A. China.
  56. Liu C, Wu L, Liu F, Ji C, Li Y (2017) Compounding method for gout suppressant Febuxostat. CN106892879A. China.
  57. Shi L, Chen X, Zhang H, Chen L, Gu C, Zhou H, Xu Z, Liu X, Yin B (2017) Preparation method for pharmaceutical crystal form of Febuxostat. CN106565627A. China.
  58. Zhai J, Fan C (2017) Process method for synthesizing thioamide. CN106928108A. China.
  59. An J-H, Lim C, Ryu H, Kim J, Kim H, Kiyonga A, Park M, Suh Y-G, Park G, Jung K (2017) Structural characterization of febuxostat/l-pyroglutamic acid cocrystal using solid-state 13C-NMR and investigational study of its water solubility. Crystals. 7 (12): 365. doi: 10.3390/cryst7120365
  60. Kang Y, Gu J, Hu X (2017) Syntheses, structure characterization and dissolution of two novel cocrystals of Febuxostat. Journal of Molecular Structure. 1130. 480-486. doi. 10.1016/j.molstruc.2016.10.044
  61. Gong J, Liu L, Zhao W (2018) Preparation method of Febuxostat intermediate. CN108440443A. China.
  62. Komiyama M, Tsuchiya H, Teramoto M, Yajima N, Kurokawa M, Minamizono K, Tsuchiya N, Kato Y, Sato Y, Dohi M (2018) Process development of Febuxostat using palladium- and copper-catalyzed C–H arylation. Organic Process Research & Development. 22 (9): 1306-1311. doi: 10.1021/acs.oprd.8b00164
  63. Shi L, Zhang Y, Huo Z, Song K, Jiang G (2018) Synthesis method for transforming impurity 3-formyl Febuxostat into Febuxostat. CN108299335A. China.
  64. Zeng P, He X, Wu J, Liu D, Cheng Z (2018) Febuxostat compound and preparation method. CN107540630A. China.
  65. Zhou L, Huang W, Zeng W, Xu H, Kang L, Feng Y, Lin Y (2018) Preparation method of Febuxostat intermediate, and application thereof in preparation of Febuxostat. CN108358866A. China.
  66. Zhang W, Xing W, Luo L (2018) Synthesis method of Febuxostat isomeride. CN108084112A. China.
  67. Huang H, Huang Q, Li K, Shi Y (2019) Preparation method of Febuxostat. CN109293597A. China.
  68. Huang H, Huang Q, Li K, Zhang H (2019) Febuxostat intermediate synthetic method. CN109574952A. China.
  69. Zhang Q, Chen B, Yan Z (2019a) Preparation method of high-purity Febuxostat. CN109912531A. China.
  70. Wang G, Xu C, Niu S, Zhu X (2019) Preparation method of Febuxostat. CN109320474 A. China.
  71. Yan J, Song S, Liu H, Yuan J (2019) One pot method' synthesis method for Febuxostat intermediate. CN109503513A. China.
  72. Zhang Y, Hong R, Yuan M, Ding D, Zhang X, Che Y, Luo H (2019) New preparation method of Febuxostat. CN110229117A. China.
  73. Zhou Y, Qu J, Chen H, Xi H, Zhang C (2019) Synthesis method of Febuxostat and intermediate thereof. CN109503512A. China.
  74. Gao L, Zhang X-R, Chen Y-F, Liao Z-L, Wang Y-Q, Zou X-Y (2019) A new febuxostat imidazolium salt hydrate: Synthesis, crystal structure, solubility, and dissolution study. Journal of Molecular Structure. 1176, 633-640. doi: 10.1016/j.molstruc.2018.08.098
  75. Zhang Y, Sui N, Jiao P, Chen X, Ma Z, Xu L (2019) One-pot synthetic method of ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate. CN109354584A. China.
  76. Bao M, Hu J, He J, Hu M, Liu J, Liu P (2019) Preparation method of Febuxostat A crystal form. CN109776448A. China.
  77. Xu Y, Yuan W, Wang H (2020) Preparation method of large-particle-size Febuxostat A crystals. CN111004191A. China.
  78. Lyu G, Guo R (2020) New preparation method of Febuxostat intermediate. CN110790720A. China.
  79. Tang J, Ma W, He H, Guo Y, Zhao F, Zhang Q (2020) Febuxostat and intermediates and synthesis thereof. CN111072591A. China.
  80. Tang J, Ma W, He H, Guo Y, Zhao F, Zhang Q (2020) Method for synthesizing Febuxostat and intermediate thereof. CN111039891A. China.
  81. Lu C (2020) Synthesis process of Febuxostat. CN111499593A. China.
  82. Liu J, Su J (2020) Method for continuously preparing Febuxostat. CN111285821A. China.
  83. Sun X, Yu K, Ge Z, Dai X (2020) Improved method for synthesizing Febuxostat key intermediate. CN112142685A. China.
  84. Xu Y, Yuan W, Zhang X (2020) High-yield synthesis method of certain specific impurity of Febuxostat. CN110878064A. China.
  85. Xu Y, Zhang X, Wang H (2020) Preparation method of a special impurity of Febuxostat. CN110642804A. China.
  86. Liu Q, Yao S, Xiao W, Wang S (2020) Synthesis method of Febuxostat impurity. CN111303071A. China.
  87. Song C, Li W (2021) Preparation method of Febuxostat intermediate. CN113620832A. China.
  88. Lai Y, Zhang F, Wang R (2021) Method for continuously producing Febuxostat by using micro-reaction device. CN113072519A. China.
  89. Peng L, Huang F, Wang Z, Zhu G, Tu Y (2021) Preparation method of Febuxostat A crystal form. CN112390766A. China.
  90. Sun Y, Yang W (2021) Preparation method of Febuxostat impurity. CN112961119A. China.
  91. Chai J, Zhang X, Li T, Li K (2022) Preparation method of 2-(3-carbamyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid. CN115093379A. China.
  92. Ji H, Chen S, Kan J (2023) Preparation method of Febuxostat. CN115772137A. China.
  93. Leng Z, Zhang Z, Yan W, Xiao C, Jiang G, Zhou W (2023) Preparation method of Febuxostat and aldehyde ester intermediate thereof. CN115572272A. China.
  94. Ungur DT, Santiso-Quinones G, Pop MM, Tamas TL, Guguta C, Stam D, Mija A, Iordache CA (2023) Febuxostat-p-toluenesulfonic acid multi-component crystal: Characterization, crystal growth and elucidation of the salt/co-crystal nature. Crystals. 13 (5): 836. doi: 10.3390/cryst13050836
  95. Manda J, Sridhar B, Subba Reddy BV (2024) Cu(I)-mediated modular approach for the synthesis of febuxostat and its analogues. Tetrahedron. 164 (134167): 134167. doi: 10.1016/j.tet.2024.134167
  96. Ungur, DT, Lanza A, Stam D, Guguta C, Iordache C, Fruth V, Santiso-Quinones G, Pop MM (2024) Crystal structure of Febuxostat marketed polymorph determined by electron diffraction and reinforced by X-ray crystallography. CrystEngComm. 26 (32): 4295-4304. doi: 10.1039/d4ce00518j

Submitted date:
11/10/2024

Reviewed date:
12/15/2024

Accepted date:
12/24/2024

Publication date:
01/14/2025

67869142a95395716c68cbe4 medjpps Articles
Links & Downloads
2789-1895 (Electronic) 2958-3101 (Printed)
Mediterr J Pharm Pharm Sci ©2025 All rights reserved.

Mediterr J Pharm Pharm Sci

Share this page
Page Sections